Brief: AN2 Therapeutics Receives Continuation Grant To Discover Novel Boron Based Therapies For Tuberculosis And Malaria
17/10/2024 12:28
Oct 17 (Reuters) - AN2 Therapeutics Inc ANTX.O :
* AN2 THERAPEUTICS RECEIVES CONTINUATION GRANT TO DISCOVER
NOVEL
BORON BASED THERAPIES FOR TUBERCULOSIS (CAUSED BY MYCOBACTERIUM
TUBERCULOSIS) AND MALARIA
Source text for Eikon: ID:nBw3KbY0sa
Further company coverage: ANTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AN2 Therapeutics
See all newsBrief: AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(C)(4)
Brief: An2 Therapeutics Announces Extension Of Funding For Tuberculosis Research Collaboration With Gsk
AN2 Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
AN2 Therapeutics Q2 net loss widens on higher R&D costs
AN2 Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview